Bharat Biotech has teamed up with Alopexx Inc to co-develop and market the broad-spectrum antimicrobial vaccine AV0328 in India and other low-income areas. The vaccine targets poly N-acetyl glucosamine found on various pathogens. Pre-clinical studies showed its effectiveness against over 15 pathogens, and a phase I trial confirmed its safety.
Related Posts
Gold price outlook: Is precious metal still a good investment bet post import duty cut? Here’s why you shouldn’t dismiss it!
The recent reduction of gold import duty from 15% to 6% resulted in an 8% drop in domestic gold prices, affecting gold ETFs and sovereign […]